Compare Bank of New York Mellon Corp (BNY) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of New York Mellon Corp vs Illumina, Inc. — how do they compare? Bank of New York Mellon Corp trades at $161.36 (market cap $108.78B), while Illumina, Inc. trades at $193.06 (market cap $29.12B). The key difference: Bank of New York Mellon Corp is far larger — about 3.7× Illumina, Inc.'s market cap, and Bank of New York Mellon Corp pays a 1.38% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| BNY | ILMN | |
|---|---|---|
Market Cap | $108.78B | $29.12B |
Sector | Financials | Health |
52-Week High | $162.35 | $205.10 |
52-Week Low | $101.00 | $91.00 |
Dividend Yield | 1.38% | — |
Enterprise Value | — | $30.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
